Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer - PubMed
4 hours ago
- #chemoresistance
- #ovarian cancer
- #quiescence
- The MRTFA/SRF pathway is identified as a critical regulator of quiescence and chemotherapy resistance in cancer.
- Quiescent ovarian cancer cells (qOvCa) show differential expression of hundreds of genes linked to the MRTFA/SRF pathway.
- Inhibition of MRTFA/SRF interaction induces quiescence across multiple cancer types, dependent on p27/Kip1 and associated with downregulation of cell cycle regulators.
- MRTFA/SRF pathway plays a dual role in chemotherapy resistance, with both inhibition and activation contributing to resistance.
- CCG257081 inhibitor treatment downregulates the stem-cell marker CD133 and sensitizes ovarian cancer cells to proteasome inhibitors.
- In vivo, CCG257081 therapy induces tumor growth-arrest and improves survival, with dual therapy (CCG081 + proteasome inhibition) leading to undetectable tumors in some cases.